Yurogen Biosystems

Executive Summary

Yurogen Biosystems is a private biotechnology company specializing in monoclonal antibody development and CRO services. Founded in 2014 in Boston, it expanded into China in 2018 and merged with ABclonal Science Inc. in 2021, a provider of biological reagents. The merger created a combined entity offering end-to-end antibody discovery, production, and reagent supply for global research and therapeutic markets. Leveraging its dual US-China footprint, Yurogen provides cost-effective solutions for drug development, diagnostics, and basic research. While still a small player, the integration with ABclonal strengthens its manufacturing capabilities and distribution network, positioning it for growth in the competitive antibody market. The company's success hinges on securing partnerships and expanding its product portfolio beyond custom services to proprietary antibody products.

Upcoming Catalysts (preview)

• Q4 2026Launch of Proprietary Monoclonal Antibody Product Line40% success
• Q3 2026Strategic Partnership with Pharma for Antibody Development50% success
• Q4 2026Expansion into European Market via Distribution Agreement35% success